Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$2.5M
Program Spending
73%
of total expenses go to program services
Total Contributions
$1.4M
Total Expenses
▼$2.6M
Total Assets
$2.1M
Total Liabilities
▼$401.1K
Net Assets
$1.7M
Officer Compensation
→$686.1K
Other Salaries
$631.3K
Investment Income
$1,584
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
Total Federal Funding
$1.1M
Awards Found
1
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | POINT OF CARE: PROVIDING AN INNOVATIVE NEW TRIAGE AND TREATMENT STRATEGY FOR CERVICAL CANCER SCREENING EFFICIENCY - PROJECT SUMMARY ALTHOUGH PREVENTABLE, CERVICAL CANCER IS A LEADING CAUSE OF MORTALITY IN LOW- AND MIDDLE-INCOME COUNTRIES (LMIC). INFECTION WITH HIGH-RISK HUMAN PAPILLOMAVIRUS (HPV) CAN LEAD TO CERVICAL PRECANCER (CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 OR HIGHER, OR CIN2+). THE WORLD HEALTH ORGANIZATION (WHO) ENDORSES BOTH ABLATION AND EXCISION TREATMENT OF CIN2+. EXCISION REQUIRES SPECIALIZED EQUIPMENT AND HIGH-LEVEL PROVIDERS AND IS GENERALLY NOT USED IN LMIC. THERMAL ABLATION (TA) IS COMMONLY USED TO TREAT CIN2+ IN LMIC. CONVENTIONAL TA IS PERFORMED WITH A NON-PORTABLE DESKTOP DEVICE THAT REQUIRES ELECTRICITY. THE WHO ENDORSED TA IN 2019 BASED LARGELY ON DATA FROM THE DESKTOP DEVICE, WHICH USES AN ENDOCERVICAL PROBE FOR EVERY TREATMENT. CURE RATES WITH THE DESKTOP DEVICE WERE 97% AFTER 18 YEARS OF FOLLOW-UP, LIKELY DUE TO USING AN ENDOCERVICAL PROBE BEING USED. ENDOCERVICAL PROBES CAN TREAT THE ENTIRE SQUAMOCOLUMNAR JUNCTION (SCJ), WHERE CERVICAL CANCER ARISES, VERSUS A FLAT PROBE ALONE. HANDHELD, INEXPENSIVE, PORTABLE, BATTERY-OPERATED TA DEVICES WERE RECENTLY CREATED FOR USE IN LMIC. NONE OF THE CURRENT HANDHELD DEVICES HAVE AN ENDOCERVICAL PROBE, AND CURE RATES IN LMIC ARE SIGNIFICANTLY LOWER AT 83%. LIGER MEDICAL (LEHI, UT) MANUFACTURES A PROTOTYPE THAT IS A COMBINATION HANDHELD TA DEVICE AND DIGITAL COLPOSCOPE, THE IRISTM, FOR USE IN LMIC. THE IRISTM WILL BE MODIFIED TO INCLUDE AN ENDOCERVICAL PROBE. IN ADDITION, THE IRISTM WILL INTEGRATE A MACHINE LEARNING (ML) ALGORITHM, AUTOMATED VISUAL EVALUATION (AVE). WHEN AVE IS COMBINED WITH HPV GENOTYPING, PRELIMINARY DATA HAS SHOWN AN AREA UNDER THE RECEIVER OPERATING CHARACTERISTICS (ROC) CURVE (AUC) OF 0.89 WITH A LIMITED TOTAL EXTREME MISCLASSIFICATION RATE OF 3.4% (CIN2+ AS NORMAL OR NORMAL AS CIN2+).THE PURPOSE OF THIS PROPOSAL IS TO MODIFY THE CURRENT IRISTM DEVICE AND CLINICALLY VALIDATE THE CHANGES THROUGH THE FOLLOWING AIMS: SPECIFIC AIM 1: TO MODIFY THE IRISTM PROTOTYPE DEVICE FOR OPTIMAL USE IN LMIC BY A) MODIFYING THE EXISTING PROBES AND B) ADAPTING IT TO HAVE A MACHINE LEARNING COMPONENT, AUTOMATED VISUAL EVALUATION (AVE); SPECIFIC AIM 2: TO CLINICALLY VALIDATE THE IRISTM ENDOCERVICAL PROBES BY ESTIMATING THE CURE RATES OF CIN2+ ONE YEAR AFTER TREATMENT; AND SPECIFIC AIM 3: TO PERFORM A RETROSPECTIVE VALIDATION OF THE AVE ALGORITHM ON IRISTM IMAGES UTILIZING HPV GENOTYPING AND HISTOPATHOLOGIC DISEASE STATUS. THE IRISTM DEVICE HAS THE POTENTIAL TO BE A GLOBAL GAME CHANGER IN THE FIELD OF CERVICAL CANCER PREVENTION. SUCCESSFUL MODIFICATION OF THE IRISTM WILL RESULT IN MORE EFFECTIVE PRECANCER TREATMENT, LESS OVER-TREATMENT, AND INCREASED EFFICIENCY OF SCREEN-AND-TREAT APPROACHES. THIS PROJECT WILL BRING EFFECTIVE POINT-OF-CARE TRIAGE AND TREATMENT TO CERVICAL CANCER ELIMINATION PROGRAMS IN LMIC. | $1.1M | FY2024 | Sep 2024 – Aug 2029 |
Department of Health and Human Services
$1.1M
POINT OF CARE: PROVIDING AN INNOVATIVE NEW TRIAGE AND TREATMENT STRATEGY FOR CERVICAL CANCER SCREENING EFFICIENCY - PROJECT SUMMARY ALTHOUGH PREVENTABLE, CERVICAL CANCER IS A LEADING CAUSE OF MORTALITY IN LOW- AND MIDDLE-INCOME COUNTRIES (LMIC). INFECTION WITH HIGH-RISK HUMAN PAPILLOMAVIRUS (HPV) CAN LEAD TO CERVICAL PRECANCER (CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 OR HIGHER, OR CIN2+). THE WORLD HEALTH ORGANIZATION (WHO) ENDORSES BOTH ABLATION AND EXCISION TREATMENT OF CIN2+. EXCISION REQUIRES SPECIALIZED EQUIPMENT AND HIGH-LEVEL PROVIDERS AND IS GENERALLY NOT USED IN LMIC. THERMAL ABLATION (TA) IS COMMONLY USED TO TREAT CIN2+ IN LMIC. CONVENTIONAL TA IS PERFORMED WITH A NON-PORTABLE DESKTOP DEVICE THAT REQUIRES ELECTRICITY. THE WHO ENDORSED TA IN 2019 BASED LARGELY ON DATA FROM THE DESKTOP DEVICE, WHICH USES AN ENDOCERVICAL PROBE FOR EVERY TREATMENT. CURE RATES WITH THE DESKTOP DEVICE WERE 97% AFTER 18 YEARS OF FOLLOW-UP, LIKELY DUE TO USING AN ENDOCERVICAL PROBE BEING USED. ENDOCERVICAL PROBES CAN TREAT THE ENTIRE SQUAMOCOLUMNAR JUNCTION (SCJ), WHERE CERVICAL CANCER ARISES, VERSUS A FLAT PROBE ALONE. HANDHELD, INEXPENSIVE, PORTABLE, BATTERY-OPERATED TA DEVICES WERE RECENTLY CREATED FOR USE IN LMIC. NONE OF THE CURRENT HANDHELD DEVICES HAVE AN ENDOCERVICAL PROBE, AND CURE RATES IN LMIC ARE SIGNIFICANTLY LOWER AT 83%. LIGER MEDICAL (LEHI, UT) MANUFACTURES A PROTOTYPE THAT IS A COMBINATION HANDHELD TA DEVICE AND DIGITAL COLPOSCOPE, THE IRISTM, FOR USE IN LMIC. THE IRISTM WILL BE MODIFIED TO INCLUDE AN ENDOCERVICAL PROBE. IN ADDITION, THE IRISTM WILL INTEGRATE A MACHINE LEARNING (ML) ALGORITHM, AUTOMATED VISUAL EVALUATION (AVE). WHEN AVE IS COMBINED WITH HPV GENOTYPING, PRELIMINARY DATA HAS SHOWN AN AREA UNDER THE RECEIVER OPERATING CHARACTERISTICS (ROC) CURVE (AUC) OF 0.89 WITH A LIMITED TOTAL EXTREME MISCLASSIFICATION RATE OF 3.4% (CIN2+ AS NORMAL OR NORMAL AS CIN2+).THE PURPOSE OF THIS PROPOSAL IS TO MODIFY THE CURRENT IRISTM DEVICE AND CLINICALLY VALIDATE THE CHANGES THROUGH THE FOLLOWING AIMS: SPECIFIC AIM 1: TO MODIFY THE IRISTM PROTOTYPE DEVICE FOR OPTIMAL USE IN LMIC BY A) MODIFYING THE EXISTING PROBES AND B) ADAPTING IT TO HAVE A MACHINE LEARNING COMPONENT, AUTOMATED VISUAL EVALUATION (AVE); SPECIFIC AIM 2: TO CLINICALLY VALIDATE THE IRISTM ENDOCERVICAL PROBES BY ESTIMATING THE CURE RATES OF CIN2+ ONE YEAR AFTER TREATMENT; AND SPECIFIC AIM 3: TO PERFORM A RETROSPECTIVE VALIDATION OF THE AVE ALGORITHM ON IRISTM IMAGES UTILIZING HPV GENOTYPING AND HISTOPATHOLOGIC DISEASE STATUS. THE IRISTM DEVICE HAS THE POTENTIAL TO BE A GLOBAL GAME CHANGER IN THE FIELD OF CERVICAL CANCER PREVENTION. SUCCESSFUL MODIFICATION OF THE IRISTM WILL RESULT IN MORE EFFECTIVE PRECANCER TREATMENT, LESS OVER-TREATMENT, AND INCREASED EFFICIENCY OF SCREEN-AND-TREAT APPROACHES. THIS PROJECT WILL BRING EFFECTIVE POINT-OF-CARE TRIAGE AND TREATMENT TO CERVICAL CANCER ELIMINATION PROGRAMS IN LMIC.
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $2.5M | $1.4M | $2.6M | $2.1M | $1.7M |
| 2023 | $2.6M | $1.6M | $2.3M | $2M | $1.8M |
| 2022 | $2M | $1.6M | $2.4M | $1.8M | $1.5M |
| 2021 | $2.6M | $2.3M | $2.5M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File | PDF not yet published by IRSView Filing → |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Dr Miriam Cremer | Founder And President | 10 | $224.4K | $0 | $0 | $224.4K |
| Karla Alfaro | Medical Director | 40 | $125.1K | $0 | $0 | $125.1K |
| Eveline Mumenthaler | Chief Operating Officer | 40 | $120K | $0 | $0 | $120K |
| Catherine Platt Thru 102024 | Chief Financial Officer | 40 | $110K | $0 | $0 | $110K |
| Dr Rachel Masch | Chief Medical Officer | 10 | $106.5K | $0 | $0 | $106.5K |
Dr Miriam Cremer
Founder And President
$224.4K
Hrs/Wk
10
Compensation
$224.4K
Related Orgs
$0
Other
$0
Karla Alfaro
Medical Director
$125.1K
Hrs/Wk
40
Compensation
$125.1K
Related Orgs
$0
Other
$0
Eveline Mumenthaler
Chief Operating Officer
$120K
Hrs/Wk
40
Compensation
$120K
Related Orgs
$0
Other
$0
Catherine Platt Thru 102024
Chief Financial Officer
$110K
Hrs/Wk
40
Compensation
$110K
Related Orgs
$0
Other
$0
Dr Rachel Masch
Chief Medical Officer
$106.5K
Hrs/Wk
10
Compensation
$106.5K
Related Orgs
$0
Other
$0
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Caroline Kant-Merada | Director | 2 | $0 | $0 | $0 | $0 |
| Deepa Desai | Director | 2 | $0 | $0 | $0 | $0 |
| Linda Lee | Director | 2 | $0 | $0 | $0 | $0 |
| Miriam Hess | Director | 2 | $0 | $0 | $0 | $0 |
| Ricardo Pedormo | Director | 5 | $0 | $0 | $0 | $0 |
Caroline Kant-Merada
Director
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Deepa Desai
Director
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Linda Lee
Director
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
| $2M |
| $1.9M |
| 2020 | $2.4M | $1.8M | $2.5M | $1.9M | $1.7M |
| 2019 | $2.9M | $2.4M | $2.3M | $2M | $1.9M |
| 2018 | $2.4M | $1.5M | $2.4M | $1.4M | $1.3M |
| 2017 | $1.6M | $1.6M | $2M | $1.4M | $1.2M |
| 2016 | $2.2M | $2.2M | $1.9M | $1.8M | $1.7M |
| 2015 | $1.8M | $1.8M | $1.7M | $1.5M | $1.4M |
| 2014 | $1.4M | $1.4M | $1.2M | $1.5M | $1.2M |
| 2013 | $205.1K | $204.7K | $914.2K | $122.4K | -$5,189 |
| 2012 | $1.4M | $1.4M | $755.4K | $723.2K | $693.3K |
| 2011 | $716.3K | $715.7K | $763.4K | $754.7K | $30.8K |
| 2010 | $624.9K | $623.4K | $673.9K | $279.1K | $216.3K |
PDF not yet published by IRSView Filing → |
| 2021 | 990 | DataIRS e-File | PDF not yet published by IRSView Filing → |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data | PDF not yet published by IRS |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | Data |
| 2009 | 990 | — |
| 2008 | 990-EZ | — |
| 2007 | 990-EZ | — |
Miriam Hess
Director
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Ricardo Pedormo
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0